103 completed, 13 terminated, 13 unknown, 11 recruiting. 62 Phase 3, 34 Phase 2, 21 Phase 4, 20 Phase 1, 10 Not applicable.
Follow Mesalamine: new trials by email Literature Review of Mesalamine trials Research Report on Mesalamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC Etrasimod, mesalazine - Etrasimod, Mesalazine | Phase 4 | Not yet recruiting | Sir Run Run Shaw Hospital | 320 | 2026-07-31 | 2026-08-24 |
| ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea mesalazine, ND-12, ND-12/H-6 - Diarrhea Chronic, UC - Ulcerative Colitis | Early Phase 1 | Recruiting | The Second Hospital of Nanjing Medical University | 36 | 2026-07-20 | 2026-08-17 |
| Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis. Acupuncture, Sham acupuncture, Mesalazine - Ulcerative Colitis | Not applicable | Recruiting | Qin Yu | 66 | 2026-02-01 | 2026-08-25 |
| Desloratadine in Patients With Ulcerative Colitis Desloratadine, mesalamine - Ulcerative Colitis (UC), Ulcerative Colitis | Phase 2 | Recruiting | Tanta University | 44 | 2026-01-26 | 2026-01-29 |
| Pentoxifylline in Patients With Ulcerative Colitis Mesalamine, Pentoxifylline - Inflammatory Bowel Diseases | Phase 2 | Recruiting | Ihab Elsayed Hassan | 60 | 2026-01-20 | 2026-04-15 |
| A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis Mesalamine, Placebo - Ulcerative Colitis (UC) | Phase 3 | Withdrawn | AbbVie | 2025-09-15 | 2025-08-12 | |
| Rupatadine in Patients With Ulcerative Colitis Mesalamine, Rupatadine - Ulcerative Colitis | Phase 2 | Recruiting | Alexandria University | 60 | 2025-07-15 | 2025-11-19 |
| Nitazoxanide in Patients With Ulcerative Colitis Mesalamine, Nitazoxanide - Ulcerative Colitis | Phase 2 | Recruiting | Alexandria University | 70 | 2025-05-30 | 2025-06-27 |
| Combined Application of EEN in the Induction of Remission in PUC exclusive enteral nutrition, regular food - Exclusive Enteral Nutrition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Children's Hospital of Fudan University | 40 | 2025-03-01 | 2024-07-03 |
| Beneficial Effect of Silymarin in Ulcerative Colitis Silymarin, Mesalamine, Azathioprine - Ulcerative Colitis | Phase 2 | Recruiting | Tanta University | 44 | 2025-02-01 | 2025-03-05 |
| TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS Tofacitinib, Tofacitinib plus mesalamine - Ulcerative Colitis | Phase 4 | Not yet recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 75 | 2024-10-01 | 2024-10-03 |
| Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine Febuxostat, Mesalamine - Ulcerative Colitis | Early Phase 1 | Not yet recruiting | Tanta University | 46 | 2024-09-01 | 2024-07-29 |
| Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) Mesalamine - Immune-related Adverse Event, Diarrhea | Phase 2 | Recruiting | AHS Cancer Control Alberta | 20 | 2024-08-20 | 2026-11-04 |
| A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis 5-ASA (5-Aminosalicylate), Colon Endoscopy Procedure, Blood Routine Test at 4-week - Ul | Completed | Xijing Hospital of Digestive Diseases | 180 | 2024-08-01 | 2025-11-25 | |
| Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis. Mesalazine - Colitis, Ulcerative | Phase 3 | Unknown | Faes Farma, S.A. | 376 | 2024-03-01 | 2023-12-19 |
| Minocyclin in Ulcerative Colitis as Added on Therapy Mesalazine, Minocycline - Inflammatory Bowel Diseases | Phase 2 | Completed | Mostafa Bahaa | 46 | 2024-01-22 | 2025-11-18 |
| Alpha Lipoic Acid in Ulcerative Colitis "Mesalamine" and "alpha-lipoic acid", "Mesalamine" and "Placebo" - Ulcerative Colitis, Ulcerative Colitis (UC) | Not applicable | Completed | Tanta University | 60 | 2023-10-01 | 2026-09-29 |
| Dapagliflozin in Patients With Ulcerative Colitis Mesalamine, Dapagliflozin 10mg Tab - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 60 | 2023-08-20 | 2026-09-21 |
| Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis Mesalamine, Nifuroxazide - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 50 | 2023-08-20 | 2026-10-13 |
| Repurposing Fenofibrate in Modulating AMPK/NLRP3 Inflammasome in Patients With Ulcerative Colitis Mesalamine, Fenofibrate - Inflammatory Bowel Diseases | Phase 2 | Completed | Tanta University | 70 | 2023-03-20 | 2026-10-13 |
Showing 20 of 148. Sign in to see all of them.
Colitis, Ulcerative (83) · Inflammatory Bowel Diseases (19) · Crohn Disease (12) · Colitis (6) · Diverticulitis (5) · Irritable Bowel Syndrome (5) · Diarrhea (4) · Recurrence (4) · Proctitis (3) · Ulcer (3) · Abdominal Pain (2) · Colorectal Neoplasms (2) · Colorectal Neoplasms, Hereditary Nonpolyposis (2) · Diverticular Diseases (2) · Gastrointestinal Diseases (2)
Shire (15) · Dr. Falk Pharma GmbH (12) · Ferring Pharmaceuticals (12) · Tanta University (9) · Warner Chilcott (8) · Tillotts Pharma AG (7) · Bausch Health Americas, Inc. (4) · SOFAR S.p.A. (4) · Mostafa Bahaa (3) · Xijing Hospital of Digestive Diseases (3) · Alexandria University (2) · Children's Hospital of Fudan University (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Sheba Medical Center (2) · The Second Hospital of Nanjing Medical University (2)
United States (47) · Germany (18) · Canada (16) · China (16) · Egypt (14) · Italy (11) · Poland (11) · France (9) · Netherlands (9) · United Kingdom (9) · Belgium (8) · Hungary (8) · India (8) · Sweden (8) · Israel (7)
Wolfgang Kruis, Professor (4) · Piotr Krzeski, MD (2) · Stephan Miehlke, Professor (2) · Ying Huang (2) · Ajit Sood, DM (1) · Alessandro Armuzzi (1) · Alon Lang, MD (1) · Ana Balske, MD, PhD (1) · Andreas Tromm, Professor (1) · Ann-Sofie Backman, MD PhD (1)
PMID 24868146, PMID 21255059, PMID 21385195, PMID 25038431, PMID 28543263, PMID 28707787, PMID 28707796, PMID 32801008, PMID 40013523, PMID 12851164, PMID 16984503, PMID 17241860, PMID 18272546, PMID 18671232, PMID 18832520, PMID 20551460, PMID 21070781, PMID 21138455, PMID 21453882, PMID 21837775, PMID 22605655, PMID 22892337, PMID 23414061, PMID 23426454, PMID 23451806, PMID 23528626, PMID 23754545, PMID 23957734, PMID 24440672, PMID 24793028, PMID 25189855, PMID 25192498, PMID 25193617, PMID 25419597, PMID 25533646, PMID 25545673, PMID 25724700, PMID 25765462, PMID 26893546, PMID 26898569, PMID 26905266, PMID 27496381, PMID 27556065, PMID 28274254, PMID 28568974, PMID 28939374, PMID 29361097, PMID 29702300, PMID 30195447, PMID 30243583
2004 (5), 2009 (3), 2015 (3), 2008 (1), K24AI001610 (1), K24DK078228 (1), U34DK090804 (1)